Stock·NASDAQ·Consumer Defensive
Mondelēz International, Inc. (MDLZ)
- Market cap
- $80.37B
- P/E
- 23.15
- Dividend yield
- 3.21%
- Street target
- $70.00median of 23 analysts
- 52-week range
- $51.20 $66.65
MDLZ stock forecast today
Where MDLZ stands today, and what CleaRank Financial AI makes of it.
MDLZ at a glance
Mondelēz International, Inc. (MDLZ): Buy, 67/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($61.82 and $60.25).
- Earnings MDLZ beat estimates in 6 of the 7 reports in our data, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $8.7M and made no open-market purchases over the last 18 months.
- Valuation P/E of 23.2 against 24.2 for the Consumer Defensive sector: broadly in line with peers (-4%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Mondelēz International, Inc. (MDLZ) Buy, with a model score of 67/100.
The trend lifts the score most: the price is 4.52% above its 200-day average and 1.86% above its 50-day average, and the 50-day average is 2.62% above the 200-day. The 50-day average stands at $61.82 and the 200-day at $60.25. Over the past year the price rose 3.62%.
Only on CleaRank
Figures we compute ourselves from MDLZ's own price, earnings and insider-filing history. Tap one to see it in context.
MDLZ stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $62.97 is 1.9% above the 50-day simple moving average of $61.82.Price above its 200-day average ›
The price is 4.5% above the 200-day simple moving average of $60.25.50-day average above the 200-day ›
The 50-day average ($61.82) is 2.6% above the 200-day average ($60.25), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 76% of its 52-week range, between $51.20 and $66.65.
MDLZ share price
Pick a period: each tab shows how far MDLZ has moved over it, to the last close.
Today's trading
Where MDLZ sits inside today's range and its 52-week range.
MDLZ fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 23.15 is 4.3% below the Consumer Defensive median of 24.2.P/S below the sector median ›
The price-to-sales ratio of 2.05 is 6.7% below the sector median of 2.2.Profitable over the last 12 months ›
Net income over the last 12 months was $2.6B on revenue of $39.3B, a net margin of 6.7%.Beat estimates in most recent reports ›
MDLZ beat the EPS estimate in 6 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 3.21%, or $2.02 a share a year.
Key statistics
The headline figures for MDLZ.
As of October 26, 2026, MDLZ trades at $62.97, with a market value of $80.37B, a P/E ratio of 23.15 and a dividend yield of 3.21%.
What the numbers say
CleaRank Financial AI's reading of MDLZ's valuation, growth and risks.
MDLZ trades at 23.46 times earnings, compared with a Consumer Defensive median of 24.2. That makes the P/E broadly in line with peers, and it sits 3.1% below the sector median P/E. On sales, the P/S of 2.05 is 6.8% below the sector median of 2.2. Trailing earnings stand at $2.72 per share.
Profitability shows a net margin of 6.7% and an operating margin of 21.98%. It reports a return on equity of 13.34%, below the sector median of 19.7%. It also reports debt-to-equity of 0.83 and a trailing dividend yield of 3.21% ($2.02 a share a year).
The most recent available report in our data, dated April 28, 2026, showed MDLZ earning $0.67 a share against an analyst estimate of $0.61. That was a beat by 9.84%. In the first session after the report, the share price moved up 4.27%.
MDLZ beat the EPS estimate in 6 of the 7 reports in our data, but beats have not guaranteed gains: the stock fell the next day after 3 of them. Analysts' average EPS estimate for this fiscal year is $3.05, which would be growth of 4.4%, and $3.36 for next year (growth of 10.2%).
MDLZ's average daily move is 1.51% with a beta of 0.39 against the S&P 500. Over the last 18 months, insider sales totalled $8.7M with no open-market purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
MDLZ against the Consumer Defensive sector
How MDLZ compares with the median Consumer Defensive stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-4% difference), suggesting fair market pricing relative to industry standards.
Return vs SPY: Since May 14, 2025, MDLZ has lost 0.9% against a gain of 30.2% for SPY.
Performance against SPY
MDLZ and the S&P 500 (SPY) over the same days.
Revenue and earnings
How much MDLZ sells, and how much of it becomes profit.
Revenue growth: Revenue grew 5.8% in FY2025 to $38.5B, from $36.4B a year earlier.
Profit margin: The net margin was 6.4% in FY2025, down from 12.7% the year before.
Profitable: MDLZ earned $2.5B in FY2025.
Earnings reality check
Did MDLZ beat what analysts expected, and how did the stock react?
Earnings record: MDLZ beat the analyst estimate in 6 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Apr 28, 2026after close | $0.61 | $0.67 | +9.84% | +4.27% | +4.82% |
| Feb 3, 2026after close | $0.70 | $0.72 | +2.86% | -0.12% | +1.98% |
| Oct 28, 2025after close | $0.71 | $0.73 | +2.82% | -3.92% | -6.86% |
| Jul 29, 2025after close | $0.68 | $0.73 | +7.35% | -6.61% | -10.63% |
| Apr 29, 2025after close | $0.66 | $0.74 | +12.12% | +3.78% | +2.83% |
| Feb 4, 2025after close | $0.65 | $0.65 | +0.00% | +2.33% | +7.72% |
| Oct 29, 2024after close | $0.85 | $0.99 | +16.47% | +0.93% | -0.14% |
Reports after April 28, 2026 are not yet in our data.
As of October 26, 2026, MDLZ has beaten the analyst EPS estimate in 6 of the 7 reports in our data and fell in the first trading session after 3 of those beats; its most recent report in our data, on April 28, 2026, came in 9.84% above the estimate and the stock moved +4.27% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
MDLZ AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 54.2, in neutral territory.RSI above 50 ›
An RSI of 54.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of MDLZ
The score, the reasoning behind it, and what could move the price next.
Mondelēz International, Inc. (MDLZ) sits in an uptrend, with the price above both of its moving averages. At $62.97, the stock is 1.86% above its 50-day average of $61.82 and 4.52% above its 200-day average of $60.25. That places it at 76% of its 52-week range, and the price is 5.52% below the 52-week high of $66.65.
The price is up over each of these periods: 4.51% over the past month, 3.79% over the past three months and 3.62% over the past year. The price fell 1.30% in the last session on volume 29.4% below its average. On momentum, the 14-day RSI reads 54.2, in the neutral zone, with the MACD line positive.
Earnings beat ›
The April 28, 2026 report beat the EPS estimate by 9.84%, and the share price rose 4.27% in the first session after it.
Source: Earnings report, April 28, 2026Rating reaffirmed ›
Barclays kept its Overweight rating on October 16, 2026.
Source: Analyst action, Barclays, October 16, 2026
- Keep an eye on the two closest levels: the 52-week high at $66.65, which sits above the price, and the 20-day EMA at $62.29, which sits below it.
- The 14-day RSI is 54.2, neutral, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- Following the April 28, 2026 report, the share price climbed 4.27% in the first session. Across the 7 reports in our data, MDLZ has beaten estimates in 6 of them.
MDLZ is trading above its 50-day and 200-day moving averages ($61.82 and $60.25), and that keeps the trend up. A drop through the 50-day would be the first sign of weakness. The closest level beneath the price is the 20-day EMA, at $62.29.
Overhead, the next level the price would meet is the 52-week high of $66.65. The 14-day RSI sits at 54.2, which is neutral, in the 40 to 60 band.
Technical indicators
Momentum and trend for MDLZ, from its daily closes.
As of October 26, 2026, with MDLZ at $62.97, its 14-day RSI is 54.2 (neutral territory), its 50-day simple moving average is $61.82 and its 200-day is $60.25.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What MDLZ moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, MDLZ's 1-year correlation of daily returns is -0.02 with S&P 500 (SPY), -0.15 with Nasdaq 100 (QQQ), -0.12 with Bitcoin (BTC) and +0.01 with gold (XAU).
MDLZ price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
15 of 23 analysts rate it a buy or strong buy, 8 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $70.00 is 11.2% above the price.More buy ratings than three months ago ›
15 of 23 rate it a buy now, against 15 of 24 three months ago.
MDLZ Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 16, 2026 | Barclays | Maintains | Overweight |
| Oct 16, 2026 | JP Morgan | Maintains | Overweight |
| Oct 5, 2026 | Wells Fargo | Maintains | Overweight |
| Jul 30, 2026 | Barclays | Maintains | Overweight |
| Jul 29, 2026 | BNP Paribas | Maintains | Outperform |
| Jul 29, 2026 | JP Morgan | Maintains | Overweight |
As of October 26, 2026, 23 Wall Street analysts cover MDLZ: 15 rate it a buy or strong buy, 8 a hold and 0 a sell or strong sell. Their 12-month price targets range from $55.00 to $77.00. The median MDLZ price target is $70.00, 11.2% above the price of $62.97.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
MDLZ trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
MDLZ trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from MDLZ's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much MDLZ tends to move, against the market and on its own.
MDLZ price history and drawdowns
MDLZ's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.51% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 28.7%, from May 2023 to January 2026; the price is still 10.7% below that peak.Most 1-year holds ended higher ›
67% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $18,218, against $42,015 in the S&P 500 (SPY).
MDLZ Drawdowns & Recovery
As of October 26, 2026, MDLZ's worst peak-to-trough fall over the last 10 years with dividends reinvested was -28.7% (May 2023 to January 2026); it is still 10.7% below that peak, and 67% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into MDLZ in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: MDLZ trailed the S&P 500 over this period: $18,218 against $42,015.
A $10,000 investment in MDLZ in October 2016 would be worth about $18,218 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to MDLZ, and which have not.
Strongest month, November: an average of +2.56%, up in 5 of 10 years.
Weakest month, October: an average of -2.22%, up in 3 of 9 years.
This month, October: has averaged -2.22%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, MDLZ's strongest calendar month has been November (average +2.56%, up in 5 of 10 years) and its weakest October (average -2.22%, up in 3 of 9 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
MDLZ stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in MDLZ, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in MDLZ today could grow to about $12,188 by 2030 in the base case, with a 90th-percentile outcome near $20,963 and a 10th-percentile outcome around $7,087. The simulation models price only; at today's 3.21% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
MDLZ Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $76.75 for MDLZ by 2030 in the base case, from $62.97 today (1.2x over 4 years). The 10th-percentile path ends near $44.63. These are outcomes of a Monte Carlo simulation run on MDLZ's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $50.45 | $66.16 | $86.77 | |
| 2028 | $47.38 | $69.52 | $102 | |
| 2029 | $45.67 | $73.05 | $117 | |
| 2030 | $44.63 | $76.75 | $132 |
Method: a lognormal simulation of MDLZ's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
MDLZ insider trading
What the people running the company have bought and sold.
MDLZ insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought MDLZ shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, MDLZ insiders reported 3 open-market sales worth $8.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Luca Zaramella
Chief Operating Officer
|
Option | 22.6K | $975.0K |
| Aug 19, 2026 | De Put Dirk Van
Chief Executive Officer
|
Sell | 133.6K | $8.6M |
| Aug 19, 2026 | De Put Dirk Van
Chief Executive Officer
|
Option | 133.6K | $5.6M |
| Jul 1, 2026 | Amit Banati
Chief Financial Officer
|
Grant | 20.4K | - |
| May 20, 2026 | Ertharin Cousin
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Cees T Hart
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Nancy Mckinstry
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Brian James Mcnamara
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Jorge S Mesquita
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Jane Hamilton Nielsen
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Paula A Price
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Patrick T Siewert
Director
|
Grant | 3.5K | - |
| May 20, 2026 | Michael A Todman
Director
|
Grant | 3.5K | - |
| May 1, 2026 | Brian Stevens
Officer
|
Sell | 64 | $3.9K |
| Apr 30, 2026 | Brian Stevens
Officer
|
Grant | 20 | - |
| Feb 13, 2026 | Gustavo Carlos Valle
Officer
|
Sell | 3.0K | $186.0K |
| Feb 11, 2026 | Deepak D Iyer
Officer
|
Grant | 28.5K | - |
| Feb 11, 2026 | Volker Kuhn
Officer
|
Grant | 20.8K | - |
| Feb 11, 2026 | Stephanie Lilak
Officer
|
Grant | 14.8K | - |
| Feb 11, 2026 | Mariano Lozano
Officer
|
Grant | 29.4K | - |
| Feb 11, 2026 | Martin Renaud
Officer
|
Grant | 37.8K | - |
| Feb 11, 2026 | Brian Stevens
Officer
|
Grant | 2.0K | - |
| Feb 11, 2026 | Gustavo Carlos Valle
Officer
|
Grant | 49.2K | - |
| Feb 11, 2026 | De Put Dirk Van
Chief Executive Officer
|
Grant | 239.4K | - |
| Feb 11, 2026 | Luca Zaramella
Chief Operating Officer
|
Grant | 96.4K | - |
| May 21, 2025 | Ertharin Cousin
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Nancy Mckinstry
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Brian James Mcnamara
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Jorge S Mesquita
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Jane Hamilton Nielsen
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Paula A Price
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Patrick T Siewert
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Hart Cees T
Director
|
Grant | 3.0K | - |
| May 21, 2025 | Michael A Todman
Director
|
Grant | 3.0K | - |
Source: TwelveData, from SEC Form 4 filings
MDLZ stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.